Russell Investments Group Ltd. increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 40.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 86,239 shares of the biotechnology company’s stock after purchasing an additional 24,884 shares during the period. Russell Investments Group Ltd.’s holdings in United Therapeutics were worth $45,617,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of UTHR. Maryland State Retirement & Pension System raised its holdings in United Therapeutics by 10.0% during the 3rd quarter. Maryland State Retirement & Pension System now owns 2,407 shares of the biotechnology company’s stock worth $1,304,000 after buying an additional 218 shares during the period. Ritholtz Wealth Management boosted its holdings in shares of United Therapeutics by 33.1% in the third quarter. Ritholtz Wealth Management now owns 2,536 shares of the biotechnology company’s stock valued at $1,374,000 after buying an additional 631 shares during the period. Jefferies Financial Group Inc. boosted its holdings in shares of United Therapeutics by 4.2% in the third quarter. Jefferies Financial Group Inc. now owns 6,975 shares of the biotechnology company’s stock valued at $3,780,000 after buying an additional 278 shares during the period. Machina Capital S.A.S. boosted its holdings in shares of United Therapeutics by 288.1% in the third quarter. Machina Capital S.A.S. now owns 3,524 shares of the biotechnology company’s stock valued at $1,910,000 after buying an additional 2,616 shares during the period. Finally, Illinois Municipal Retirement Fund increased its position in shares of United Therapeutics by 2.5% during the third quarter. Illinois Municipal Retirement Fund now owns 40,014 shares of the biotechnology company’s stock worth $21,683,000 after acquiring an additional 972 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on UTHR shares. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $697.00 to $725.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 price objective on shares of United Therapeutics in a research report on Monday, October 26th. Leerink Partners upped their target price on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. TD Cowen increased their target price on United Therapeutics from $675.00 to $700.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, BTIG Research increased their target price on United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $676.40.
United Therapeutics Stock Performance
Shares of United Therapeutics stock opened at $591.17 on Monday. The firm has a market cap of $25.18 billion, a PE ratio of 22.31, a P/E/G ratio of 3.93 and a beta of 0.49. The business’s 50 day simple moving average is $542.60 and its 200 day simple moving average is $536.37. United Therapeutics Corporation has a 52-week low of $455.63 and a 52-week high of $614.23.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. During the same period last year, the company earned $7.16 EPS. The company’s revenue was up 4.1% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 25.08 EPS for the current year.
United Therapeutics declared that its board has approved a share buyback program on Thursday, October 22nd that allows the company to repurchase $2 billion in shares. This buyback authorization allows the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
Insider Transactions at United Therapeutics
In related news, Director Christopher Patusky sold 1,210 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $580.00, for a total value of $701,800.00. Following the completion of the transaction, the director owned 2,140 shares of the company’s stock, valued at approximately $1,241,200. This trade represents a 36.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $598.67, for a total transaction of $4,968,961.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $27,043,121.24. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 402,738 shares of company stock valued at $216,162,401 over the last 90 days. 8.60% of the stock is owned by corporate insiders.
United Therapeutics Company Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Featured Stories
- Five stocks we like better than United Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
